Hope for people with FOP disease as three drugs enter clinical trial – and one could be approved by next year
Fibrodysplasia ossificans progressiva (FOP) is a rare, genetic disease in which damaged muscle and soft tissue turn into bone It affects just 800 people worldwide and there is currently no known cure Three drugs have entered clinical trials as potential treatments for the condition They target the genes and proteins responsible for the hyperactive bone growth